A specific role for AKT3 in the genesis of ovarian cancer through modulation of G2-M phase transition

Cancer Research

Volumn 66, Issue 24, 2006, Pages 11718-11725

  Cristiano, Briony E ^a   Chan, Joanna C ^a,e   Hannan, Katherine M ^a   Lundie, Nicole A ^a   Marmy Conus, Nelly J ^a   Campbell, Ian G ^a,b   Phillips, Wayne A ^a,b   Robbie, Melissa ^d   Hannan, Ross D ^a,b,c,e   Pearson, Richard B ^a,b,c,e  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; SHORT HAIRPIN RNA;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL COUNT; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PURIFICATION; HUMAN; HUMAN CELL; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL DIVISION; CULTURE MEDIA; FEMALE; G2 PHASE; GLUTATHIONE TRANSFERASE; HUMANS; KIDNEY; KINETICS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE;

EID: 33846252336     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1968     Document Type: Article

References (47)

1. Pusztai L, Siddik ZH, Mills GB, Bast RCJ. Physiologic and pathologic drug resistance in ovarian carcinoma-a hypothesis based on a clonal progression model [see comments]. Acta Oncol 1998;37:629-40.
2. Sabbatini P, McCormick F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J Biol Chem 1999;274:24263-9.
3. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer [see comments]. Nat Genet 1999;21:99-102.
4. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81.
5. Yuan ZQ, Sun M, Feldman RI, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000;19:2324-30.
6. Page C, Lin HJ, Jin Y, et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000;20:407-16.
7. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002;62:1087-92.
8. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 2001;98:10983-5.
9. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62.
10. Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004;23:5853-7.
11. Easton RM, Cho H, Roovers K, et al. Role for Akt3/ protein kinase Bγ in attainment of normal brain size. Mol Cell Biol 2005;25:1869-78.
12. Sun M, Wang G, Paciga JE, et al. AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001;159:431-7.
13. Altomare DA, Tanno S, De Rienzo A, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 2003;88:470-6.
14. Nakatani K, Thompson DA, Barthel A, et al. Upregulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-32.
15. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64:7002-10.
16. Michell BJ, Griffiths JE, Mitchelhill KI, et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol 1999;9:845-8.
17. Bozinovski S, Cristiano BE, Marmy-Conus NJ, Pearson RB. The synthetic peptide RPRAATF allows specific assay of Akt activity in cell lysates. Anal Biochem 2002;305:32-9.
18. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-9.
19. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol 1997;7:261-9.
20. Conus NM, Hemmings BA, Pearson RB. Differential regulation by calcium reveals distinct signaling requirements for the activation of Akt and p70S6k. J Biol Chem 1998;273:4776-82.
21. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
22. Hannan KM, Brandenburger Y, Jenkins A, et al. mTOR-Dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF{dagger}. Mol Cell Biol 2003;23:8862-77.
23. Nakatani K, Sakaue H, Thompson DA, Weigel RJ, Roth RA. Identification of a human Akt3 (protein kinase Bγ) which contains the regulatory serine phosphorylation site. Biochem Biophys Res Commun 1999;257:906-10.
24. Mende I, Malstrom S, Tsichlis PN, Vogt PK, Aoki M. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 2001;20:4419-23.
25. Lynch DK, Daly RJ. PKB-mediated negative feedback tightly regulates mitogenic signalling via Gab2. EMBO J 2002;21:72-82.
26. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004;29:233-42.
27. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004;22:4217-26.
28. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
29. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
30. Me HY, Pearline RV, Grueneberg D, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 2005;171:1023-34.
31. Liang J, Slingerland JM. Multiple roles of the PI3K/ PKB (AKT) pathway in cell cycle progression. Cell Cycle 2003;2:339-45.
32. Garcia BA, Barber CM, Hake SB, et al. Modifications of human histone H3 variants during mitosis. Biochemistry 2005;44:13202-13.
33. Okumura E, Fukuhara T, Yoshida H, et al. Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/ M-phase transition. Nat Cell Biol 2002;4:111-6.
34. Katayama K, Fujita N, Tsuruo T. Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol Cell Biol 2005;25:5725-37.
35. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-64.
36. Tschopp O, Yang ZZ, Brodbeck D, et al. Essential role of protein kinase Bγ (PKBγ/Akt3) in postnatal brain development but not in glucose homeostasis. Development 2005;132:2943-54.
37. Watanabe N, Broome M, Hunter T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J 1995;14:1878-91.
38. 2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 2005;65:4861-9.
39. Kandel ES, Skeen J, Majewski N, et al. Activation of Akt/protein kinase B overcomes a G2/M cell cycle checkpoint induced by DNA damage. Mol Cell Biol 2002;22:7831-41.
40. Shtivelman E, Sussman J, Stokoe D. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol 2002;12:919-24.
41. Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001;15:2203-8.
42. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 2001;292:1728-31.
43. Peng X-d, Xu P-Z, Chen M-L, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003;17:1352-65.
44. Yang ZZ, Tschopp O, Di-Poi N, et al. Dosage-dependent effects of Akt1/protein kinase Bα (PKBα) and Akt3/PKBγ on thymus, skin, and cardiovascular and nervous system development in mice. Mol Cell Biol 2005;25:10407-18.
45. Cheng JQ, Altomare DA, Klein MA, et al. Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 1997;14:2793-801.
46. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005;24:7482-92.
47. Kumar CC, Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene 2005;24:7493-501.